MP68-15 ELECTRICAL STIMULATION OF AFFERENT NERVES IN THE FOOT WITH TRANSCUTANEOUS ADHESIVE PAD ELECTRODES IMPROVES OVERACTIVE BLADDER SYMPTOMS IN WOMEN

Abstract

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Basic Research & Pathophysiology II1 Apr 2016MP68-15 ELECTRICAL STIMULATION OF AFFERENT NERVES IN THE FOOT WITH TRANSCUTANEOUS ADHESIVE PAD ELECTRODES IMPROVES OVERACTIVE BLADDER SYMPTOMS IN WOMEN Christopher Chermansky, Bing Shen, Jon Shepherd, Shachi Tyagi, Jeremy Reese, William de Groat, and Changfeng Tai Christopher ChermanskyChristopher Chermansky More articles by this author , Bing ShenBing Shen More articles by this author , Jon ShepherdJon Shepherd More articles by this author , Shachi TyagiShachi Tyagi More articles by this author , Jeremy ReeseJeremy Reese More articles by this author , William de GroatWilliam de Groat More articles by this author , and Changfeng TaiChangfeng Tai More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.1352AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Treatments for refractory overactive bladder (OAB) include onabotulinumtoxinA, sacral neuromodulation, and tibial neuromodulation. Yet, a non-invasive and convenient OAB treatment with no major adverse events would be ideal. We previously showed that stimulation of foot afferents in normal humans without OAB increased bladder capacity by more than 50% (an average of 200 cc) without any adverse events. We sought to determine if electrical stimulation of afferent nerves in the foot with transcutaneous adhesive pad electrodes (FootStim) improves OAB symptoms. METHODS Women with UUI from OAB underwent FootStim for 3 hours every evening for 7 days. All patients stopped OAB drug therapy 2 weeks prior. A 3-week voiding diary was obtained, and FootStim was applied during week 2 (see Figure). Transcutaneous adhesive pad electrodes were attached to the bottom of the foot to activate the lateral and medial plantar nerves. These electrodes were connected to a transcutaneous electrical nerve stimulator. Stimulation parameters included a pulse frequency of 5 Hz, a pulse width of 0.2 ms, and an intensity of 2-4 times the minimal stimulation necessary to induce a toe twitch. Responder was defined as having a statistically significant improvement in 1 or more of the measured voiding parameters. RESULTS Nineteen women completed the study, of which 16/19 (84%) responded. Incontinence frequency in all 19 women decreased from 3.7 leaks/day at baseline to 2.8 leaks/day at baseline (p=0.04), and urgency frequency decreased from 7.6 episodes/day to 6.6 episodes/day (p=0.03). Statistically significant decreases were seen in daytime voiding frequency and nocturia in 8 and 7 subjects respectively, although these differences were not significant when analyzing the entire sample size. The FootStim effect persisted for 4 days after treatment was discontinued. There were no adverse events. CONCLUSIONS FootStim in women with UUI from OAB decreased incontinence frequency and urgency frequency, and these results are comparable with pharmacotherapy. Our results support further testing of FootStim to determine ideal stimulation schedule and to test against placebo. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e894-e895 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Christopher Chermansky More articles by this author Bing Shen More articles by this author Jon Shepherd More articles by this author Shachi Tyagi More articles by this author Jeremy Reese More articles by this author William de Groat More articles by this author Changfeng Tai More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...